|View printer-friendly version|
|Chief Science Officer Tapped as Mentor for University of Pittsburg Science2008|
INC Research's Michael Corrado, MD has been selected as a mentor for the "First Look" Technology Showcase at University of Pittsburgh's 8th annual Science2008 conference.
The popular Technology Showcase features innovative, new technologies recently developed at Pitt that are now available for licensing. The Technology Showcase, scheduled on Thursday, Oct. 2nd, is organized by the University's Office of Enterprise Development and Office of Technology Management.
Dr. Corrado has been teamed up with a faculty member of the University of Pittsburgh School of Medicine who has developed a new technique for pediatric solid organ transplant. Dr. Corrado's role is to help bridge the divide between innovation to commercialization. He has worked with the scientist to position his solution for investors evaluating early stage technology companies, which includes the development of the "elevator pitch," target markets and compelling advantages over status quo.
Venture capitalists, seed investors, local company executives and other business, legal, and financial experts come to the Technology Showcase looking for exciting, cutting edge technologies.
As Chief Science Officer, Dr. Corrado is head of INC Research's Regulatory Group and has established himself as an infectious disease expert. He has been intricately involved in the complete development of numerous infectious disease compounds, from pre-clinical work through marketing application submission. Dr. Corrado has served as Primary Medical Author of seven NDAs, ten sNDAs, and several expert reports submitted to European regulatory bodies. Dr. Corrado attended the University of Pittsburgh for his undergraduate degree and received his medical degree from Meharry Medical College.
About INC Research®
INC Research is a therapeutically-focused contract research organization with an unrivaled reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric trials. The company's Trusted Process™ methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina, and now in 25 locations in 32 countries worldwide. For more information please visit www.incresearch.com.